<?xml version="1.0"?>
<law>
  <structure>
    <unit label="title" identifier="gcr" order_by="" level="1"/>
    <unit label="chapter" identifier="5-402" order_by="" level="2"/>
  </structure>
  <section_number>gcr-5-402</section_number>
  <catch_line/>
  <text>
    <section prefix="(a)">Schedule I consists of each controlled dangerous substance:<section prefix="(1)">listed in this section;</section><section prefix="(2)">added to Schedule I by the Department under &#xA7; 5-202(b) of this title; or</section><section prefix="(3)">designated as a Schedule I controlled dangerous substance by the federal government unless the Department objects under &#xA7; 5-202(f) of this title.</section></section>
    <section prefix="(b)">
      <section prefix="(1)">These substances are listed in Schedule I:<section prefix="(i)">acetylmethadol;</section><section prefix="(ii)">alfentanil;</section><section prefix="(iii)">allylprodine;</section><section prefix="(iv)">alphacetylmethadol, except levoalphacetylmethadol;</section><section prefix="(v)">alphameprodine;</section><section prefix="(vi)">alphamethadol;</section><section prefix="(vii)">benzethidine;</section><section prefix="(viii)">betacetylmethadol;</section><section prefix="(ix)">betameprodine;</section><section prefix="(x)">betamethadol;</section><section prefix="(xi)">betaprodine;</section><section prefix="(xii)">clonitazene;</section><section prefix="(xiii)">dextromoramide;</section><section prefix="(xiv)">dextrorphan;</section><section prefix="(xv)">diampromide;</section><section prefix="(xvi)">diethylthiambutene;</section><section prefix="(xvii)">dimenoxadol;</section><section prefix="(xviii)">difenoxin;</section><section prefix="(xix)">dimepheptanol;</section><section prefix="(xx)">dimethylthiambutene;</section><section prefix="(xxi)">dioxaphetyl butyrate;</section><section prefix="(xxii)">dipipanone;</section><section prefix="(xxiii)">ethylmethylthiambutene;</section><section prefix="(xxiv)">etonitazene;</section><section prefix="(xxv)">etoxeridine;</section><section prefix="(xxvi)">furethidine;</section><section prefix="(xxvii)">hydroxypethidine;</section><section prefix="(xxviii)">ketobemidone;</section><section prefix="(xxix)">levomoramide;</section><section prefix="(xxx)">levophenacylmorphan;</section><section prefix="(xxxi)">morpheridine;</section><section prefix="(xxxii)">noracymethadol;</section><section prefix="(xxxiii)">norlevorphanol;</section><section prefix="(xxxiv)">normethadone;</section><section prefix="(xxxv)">norpipanone;</section><section prefix="(xxxvi)">phenadoxone;</section><section prefix="(xxxvii)">phenampromide;</section><section prefix="(xxxviii)">phenomorphan;</section><section prefix="(xxxix)">phenoperidine;</section><section prefix="(xl)">piritramide;</section><section prefix="(xli)">proheptazine;</section><section prefix="(xlii)">properidine;</section><section prefix="(xliii)">propiram;</section><section prefix="(xliv)">racemoramide; and</section><section prefix="(xlv)">trimeperidine.</section></section>
      <section prefix="(2)">Unless specifically excepted under this subtitle, an isomer, ester, ether, or salt of a substance listed in this subsection or a salt of the isomer, ester, or ether is a substance listed in Schedule I if the existence of the isomer, ester, ether, or salt is possible within the specific chemical designation.</section>
    </section>
    <section prefix="(c)">
      <section prefix="(1)">These opium derivatives are substances listed in Schedule I:<section prefix="(i)">acetorphine;</section><section prefix="(ii)">acetyldihydrocodeine;</section><section prefix="(iii)">acetylocodone;</section><section prefix="(iv)">benzylmorphine;</section><section prefix="(v)">codeine methylbromide;</section><section prefix="(vi)">codeine-N-oxide;</section><section prefix="(vii)">codoxime;</section><section prefix="(viii)">cyprenorphine;</section><section prefix="(ix)">desomorphine;</section><section prefix="(x)">dihydromorphine;</section><section prefix="(xi)">drotebanol;</section><section prefix="(xii)">ethylmorphine methyliodide;</section><section prefix="(xiii)">etorphine;</section><section prefix="(xiv)">etorphine 3-methylether;</section><section prefix="(xv)">heroin;</section><section prefix="(xvi)">hydromorphinol;</section><section prefix="(xvii)">methyldesorphine;</section><section prefix="(xviii)">methyldihydromorphinone;</section><section prefix="(xix)">methylhydromorphine;</section><section prefix="(xx)">morphine methylbromide;</section><section prefix="(xxi)">morphine methylchloride;</section><section prefix="(xxii)">morphine methylsulfonate;</section><section prefix="(xxiii)">morphine-N-oxide;</section><section prefix="(xxiv)">myrophine;</section><section prefix="(xxv)">nicocodeine;</section><section prefix="(xxvi)">nicodicodine;</section><section prefix="(xxvii)">nicomorphine;</section><section prefix="(xxviii)">norcodeine;</section><section prefix="(xxix)">normorphine;</section><section prefix="(xxx)">pholcodine; and</section><section prefix="(xxxi)">thebacon.</section></section>
      <section prefix="(2)">Unless specifically excepted under this subtitle, a salt, isomer, or salt of an isomer of a substance listed in this subsection is a Schedule I substance if the existence of the salt, isomer, or salt of an isomer is possible within the specific chemical designation.</section>
    </section>
    <section prefix="(d)">
      <section prefix="(1)">A material, compound, mixture, or preparation that contains any of the following hallucinogenic or hallucinogenic-like substances is a substance listed in Schedule I:<section prefix="(i)">bufotenine;</section><section prefix="(ii)">diethyltryptamine;</section><section prefix="(iii)">dimethyltryptamine;</section><section prefix="(iv)">4-methyl-2, 5-dimethoxyamphetamine;</section><section prefix="(v)">ibogaine;</section><section prefix="(vi)">lysergic acid diethylamide;</section><section prefix="(vii)">marijuana;</section><section prefix="(viii)">mescaline;</section><section prefix="(ix)">peyote;</section><section prefix="(x)">psilocybin;</section><section prefix="(xi)">psilocyn;</section><section prefix="(xii)">tetrahydrocannabinol;</section><section prefix="(xiii)">thiophene analog of phencyclidine;</section><section prefix="(xiv)">2, 5-dimethoxyamphetamine;</section><section prefix="(xv)">4-bromo-2, 5-dimethoxyamphetamine;</section><section prefix="(xvi)">4-methoxyamphetamine;</section><section prefix="(xvii)">3, 4-methylenedioxyamphetamine;</section><section prefix="(xviii)">3, 4-methylenedioxymethamphetamine (MDMA);</section><section prefix="(xix)">5-methoxy-3, 4-methylenedioxyamphetamine;</section><section prefix="(xx)">3, 4, 5-trimethoxyamphetamine;</section><section prefix="(xxi)">N-methyl-3-piperidyl benzilate;</section><section prefix="(xxii)">N-ethyl-3-piperidyl benzilate;</section><section prefix="(xxiii)">N-ethyl-1-phenylcyclohexylamine;</section><section prefix="(xxiv)">1-(1-phenylcyclohexyl)-pyrrolidine;</section><section prefix="(xxv)">1-(1-(2-thienyl)-cyclohexyl)-piperidine;</section><section prefix="(xxvi)">1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);</section><section prefix="(xxvii)">1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine (PEPAP);</section><section prefix="(xxviii)">3, 4-methylenedioxymethcathinone (methylone);</section><section prefix="(xxix)">3, 4-methylenedioxypyrovalerone (MDPV);</section><section prefix="(xxx)">4-methylmethcathinone (mephedrone);</section><section prefix="(xxxi)">4-methoxymethcathinone (methedrone);</section><section prefix="(xxxii)">4-fluoromethcathinone (flephedrone); and</section><section prefix="(xxxiii)">3-fluoromethcathinone (3-FMC).</section></section>
      <section prefix="(2)">Unless specifically excepted under this subtitle, a salt, isomer, or salt of an isomer of a substance listed in this subsection is a substance listed in Schedule I if the existence of the salt, isomer, or salt of an isomer is possible within the specific chemical designation.</section>
    </section>
    <section prefix="(e)">
      <section prefix="(1)">Unless specifically excepted under this subtitle or listed in another schedule, a material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system is a substance listed in Schedule I:<section prefix="(i)">mecloqualone;</section><section prefix="(ii)">methaqualone; and</section><section prefix="(iii)">a salt, isomer, or salt of an isomer of a substance listed in this paragraph if the existence of the salt, isomer, or salt of an isomer is possible within the specific chemical designation.</section></section>
      <section prefix="(2)">Any material, compound, mixture, or preparation that contains any of the following substances is a substance listed in Schedule I:<section prefix="(i)">3-methylfentanyl (N-3-methyl-1-(2-phenylethyl)-4-piperidyl-1-N-phenylpropanamide), its optical and geometric isomers, salts, and salts of isomers;</section><section prefix="(ii)">acetyl-alpha-methylfentanyl;</section><section prefix="(iii)">alpha-methylthiofentanyl;</section><section prefix="(iv)">benzylfentanyl;</section><section prefix="(v)">beta-hydroxy-3-methylfentanyl;</section><section prefix="(vi)">beta-hydroxyfentanyl;</section><section prefix="(vii)">thenylfentanyl;</section><section prefix="(viii)">thiofentanyl; and</section><section prefix="(ix)">3-methylthiofentanyl.</section></section>
    </section>
    <section prefix="(f)">
      <section prefix="(1)">In this subsection:<section prefix="(i)">"controlled dangerous substance analogue" means a substance:</section><section prefix="(ii)">"controlled dangerous substance analogue" does not include:</section></section>
      <section prefix="(2)">To the extent intended for human consumption, each controlled dangerous substance analogue is a substance listed in Schedule I.</section>
    </section>
    <section prefix="(g)">The Department may not add a substance to Schedule I under &#xA7; 5-202 of this title unless the Department finds:<section prefix="(1)">a high potential for abuse of the substance;</section><section prefix="(2)">no accepted medical use in the United States for the substance; and</section><section prefix="(3)">a lack of accepted safety for use of the substance under medical supervision.</section></section>
  </text>
</law>
